Ep.63 - FDA To Review 12 Peptides What It Means Moving Forward

About this video

Seeds and co-hosts discuss the FDA announcement that it will re-review a group of peptides previously placed in a category that blocked US compounding pharmacies from preparing them. They explain the compounding category system, the role of the advisory committee tasked with weighing safety, immunogenicity, manufacturing of the active ingredient, and human efficacy, and scheduled review meetings. Seeds stresses an evidence hierarchy from molecular pathways through cell and animal work to human safety and efficacy, warns against marketing mechanism as proof, and argues manufacturing quality — purity, sterility, and aggregation after injection — matters more than certificates alone. He also criticises grey-market sourcing and misuse of compounding credentials.

Key takeaways

• Compounding permission is not FDA approval of safety or efficacy, the hosts emphasise
• Judge peptide claims by where they sit on the preclinical-to-human evidence ladder
• Manufacturing and aggregation can change immunogenicity, Seeds argues, beyond what a certificate shows
• Regulatory review is framed as a safety process to engage with, not simply an obstacle

Episode details: published June 30, 2026 · 351 views · 33:21 long. Summary written by Self Growth Videos from the episode itself. The peptide and cellular-medicine concepts described are Dr. William Seeds’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: the SSRP Institute sells clinician certification in peptide therapy.

← Previous: Ep.49 - Chinese Peptides Hit Silicon Valley · Next: Ep.65 - Live Episode From Peptide World Congress 2026 →

All Dr. William Seeds videos · Dr. William Seeds profile · SSRP Institute (official site)